Silence Therapeutics plc (SLN) stock
Close on Nov 12, 2026Market cap $935.48MP/E –Yield –
Silence Therapeutics plc saw revenue fall 97.7% to $615.00K over the twelve months to Jun 30, 2026. Free cash flow was -$42.27M. At the latest close the market valued the company at $935.48M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $935.48M
- P/E ratio
- –
- Price to sales
- 1521.11
- Price to book
- 24.32
- Dividend yield
- –
- Free cash flow yield
- -4.52%
Fundamentals
- Revenue
- $615.00K
- Net income
- -$59.95M
- EPS, diluted
- -$0.43
- Free cash flow
- -$42.27M
- Book value per share
- $0.27
- Diluted shares
- 142M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $19.77
- Open
- $19.76
- Day's range
- $19.76 – $19.82
- Volume
- 659,205
- Average volume (20 days)
- 5,721,501
- Beta (5 years)
- 1.05
- 52-week range
- $4.19 – $19.86
- RSI (14 days)
- 78.0
- Volatility (1 year)
- 149.7%
- Relative volume
- 0.13×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SLN | S&P 500 | Difference | SLN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +105.2% | -2.7% | +107.9 pts | ||
| 3 months | +45.8% | -1.7% | +47.5 pts | ||
| Year to date | +225.7% | +11.9% | +213.8 pts | ||
| 1 year | +194.2% | +12.0% | +182.2 pts | ||
| 3 years | +115.2% | +78.2% | +37.0 pts | +29.1% | +21.2% |
| 5 years | -12.8% | +73.2% | −86.0 pts | -2.7% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Silence Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Update
- Update
About Silence Therapeutics
Pharmaceutical Preparations
Silence Therapeutics plc is a clinical-stage biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid to inhibit target gene expression. Utilizing its proprietary mRNAi GOLD discovery platform, the company engineers GalNAc-conjugated therapeutics designed to degrade specific messenger RNA transcripts in the liver, effectively silencing disease-associated proteins before synthesis. Silence Therapeutics targets rare and cardiometabolic diseases with limited therapies, advancing clinical and preclinical candidates including divesiran for hematological conditions like polycythemia vera, zerlasiran for cardiovascular disease, and SLN312 for lipid metabolism disorders.
Company profile, executives and historySilence Therapeutics stock: common questions
What is Silence Therapeutics's stock price?
SLN closed at $19.80 on Nov 12, 2026, up 0.15% on the day. Over the past 52 weeks it traded between $4.19 and $19.86.
What is Silence Therapeutics's market cap?
Silence Therapeutics was worth $935.48M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SLN's P/E ratio?
Silence Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
How much revenue does Silence Therapeutics make?
Silence Therapeutics reported revenue of $615.00K for the twelve months to Jun 30, 2026, down 97.7% from a year earlier.
Does Silence Therapeutics pay a dividend?
No. Silence Therapeutics has not paid a cash dividend over the last twelve months.
When does Silence Therapeutics report earnings next?
Silence Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has SLN stock performed over the past year?
Including dividends, SLN returned +194.2% over the past year, against +12.0% for the S&P 500.
Who are Silence Therapeutics's competitors?
Companies most similar to Silence Therapeutics by business, industry and size include MREO, RLYB, KRRO, SPRB, VCNX.
See a number that looks wrong?